RE:RE:Pet deal coming soon Wanbang didn't make the Sirona clinical trials a priority and it they took so long by the time they were nearing the final phases the compound was deemed generic and Wanbang abandoned it.
Sirona didn't put any timelines or milestones in the agreement as usual so Wanbang just did what they wanted. Not sure why they would continue the relationship given the past track record plus China shutting down entire cities for Covid (which could lead to supply and research delays) and notoriously known for lifting IP and making it their own.
They should have brought the existing trial information (if Wanbang parted with it) and went and partnered with Allergan on it.